No Data
No Data
This Nuvation Bio Insider Increased Their Holding In The Last Year
Insiders were net buyers of Nuvation Bio Inc.'s (NYSE:NUVB ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply follo
Nuvation Bio(NUVB.US) Director Buys US$500.09K in Common Stock
$Nuvation Bio(NUVB.US)$ Director BLICKENSTAFF KIM D purchased 172.19K shares of common stock on Jun 11, 2024 at an average price of $2.9043 for a total value of $500.09K.Source: Announcement What is s
Nuvation Bio Insider Bought Shares Worth $500,089, According to a Recent SEC Filing
Kim D Blickenstaff, Director, on June 11, 2024, executed a purchase for 172,189 shares in Nuvation Bio (NUVB) for $500,089. Following the Form 4 filing with the SEC, Blickenstaff has control over a to
Buy Rating for Nuvation Bio: Taletrectinib's Promising Efficacy and Strategic Path to Approval
Reported Saturday, Nuvation Bio Revealed Findings From The Crucial Phase 2 TRUST-I Trial Of Their Experimental ROS1 Inhibitor, Taletrectinib At The ASCO 2024
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the studyResponses were durable with
Express News | Nuvation Bio Inc : Aim to Become a Commercial-Stage Organization by End of 2025
No Data
MARKET-TEST-DUMMY : watching too